title: [MR techniques for noninvasive diagnosis of prostate cancer].
abstract: The diagnosis of prostate cancer is suggested on the basis of an elevated PSA level, abnormal digital exam, and abnormal transrectal ultrasound. US-guided biopsy is used to confirm the diagnosis, but up to 30% of prostate cancer may be missed with this approach. Meanwhile MR imaging and proton MR spectroscopy have emerged as the most sensitive additional tools for the noninvasive evaluation of prostate cancer. This article reviews the clinical indications for MRI of the prostate and summarizes new techniques such as high field strength (3 tesla) and dynamic contrast-enhanced MRI.
authors.affiliation: Radiologische Klinik, Klinikum, Rheinische Friedrich-Wilhelms Universität, Sigmund-Freud-Strasse 25, 53105, Bonn. n.morakkabati@uni-bonn.de
authors.forename: N
authors.initials: N
authors.lastname: Morakkabati-Spitz
authors.forename: P J
authors.initials: PJ
authors.lastname: Bastian
authors.forename: A
authors.initials: A
authors.lastname: Meissner
authors.forename: F
authors.initials: F
authors.lastname: Träber
authors.forename: J
authors.initials: J
authors.lastname: Gieseke
authors.forename: H H
authors.initials: HH
authors.lastname: Schild
authors.forename: S C
authors.initials: SC
authors.lastname: Müller
mesh_terms: D014408:Biomarkers, Tumor / Q000097:blood; D006801:Humans; D007091:Image Processing, Computer-Assisted; D008279:Magnetic Resonance Imaging; D009682:Magnetic Resonance Spectroscopy; D008297:Male; D009367:Neoplasm Staging; D011379:Prognosis; D011467:Prostate / Q000473:pathology; D017430:Prostate-Specific Antigen / Q000097:blood; D011471:Prostatic Neoplasms / Q000175:diagnosis* / Q000473:pathology; D014463:Ultrasonography
chemical_list: D014408:Biomarkers, Tumor; D017430:Prostate-Specific Antigen